Antibodies to native and denatured DNA in the serum of patients with schizophrenia depending on the clinical features of the disease

Smirnova L.P.; Ermakov E.A.; Boyko A.S.; Bokhan N.A.; Semke A.V.; Ivanova S.A.

doi:https://doi.org/10.17116/jnevro20161164147-51

Smirnova L.P.

Mental Health Research Institute, Tomsk

Ermakov E.A.

Mental Health Research Institute, Tomsk;
Novosibirsk State University, Novosibirsk

Boyko A.S.

Mental Health Research Institute, Tomsk

Bokhan N.A.

Nauchno-issledovatel'skiĭ institut psikhicheskogo zdorov'ia Tomskogo nauchnogo tsentra Sibirskogo otdeleniia RAMN

Semke A.V.

Nauchno-issledovatel'skiĭ institut psikhicheskogo zdorov'ia Sibirskogo otdeleniia Rossiĭskoĭ akademii meditsinskikh nauk, Tomsk

Ivanova S.A.

Nauchno-issledovatel'skiĭ institut psikhicheskogo zdorov'ia Sibirskogo otdeleniia Rossiĭskoĭ akademii meditsinskikh nauk, Tomsk

Antibodies to native and denatured DNA in the serum of patients with schizophrenia depending on the clinical features of the disease

Authors:

Smirnova L.P., Ermakov E.A., Boyko A.S., Bokhan N.A., Semke A.V., Ivanova S.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(4): 47‑51

DOI: 10.17116/jnevro20161164147-51

Read: 1841 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Smirnova LP, Ermakov EA, Boyko AS, Bokhan NA, Semke AV, Ivanova SA. Antibodies to native and denatured DNA in the serum of patients with schizophrenia depending on the clinical features of the disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(4):47‑51. (In Russ.)
https://doi.org/10.17116/jnevro20161164147-51

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

Abstract:

Objective. To study the correlations between the level of antibodies to native and denatured DNA and psychopathological symptoms and illness duration in patients with schizophrenia. Material and methods. The level of antibodies to native (double-stranded) DNA and denatured (single-stranded) DNA was studied in the serum of 50 patients with schizophrenia, including 12 patients with tardive dyskinesia (TD). The control group consisted of 30 people. Results. A significant twofold increase in antibodies to native DNA was detected in patients with TD. There was no correlation of the amount of antibodies to double-stranded DNA with the duration of disease and leading symptoms both between the groups of patients as well as in comparison with controls. A significant decrease in antibody levels to the denatured (single-stranded) DNA was found in schizophrenic patients compared to the control group (p=0.009). A significant decrease in the concentration of antibodies to single-stranded DNA in patients with increasing duration of the disease, as well as in patients with leading negative symptoms was revealed. Conclusion: The results suggest that anti-DNAantibodies may not play a major role in the pathogenesis of schizophrenia.

Keywords:

schizophrenia

anti-DNAantibodies

tardive dyskinesia

positive symptoms

negative symptoms

duration of disease

Authors:

Smirnova L.P.

Mental Health Research Institute, Tomsk

Ermakov E.A.

Mental Health Research Institute, Tomsk;
Novosibirsk State University, Novosibirsk

Boyko A.S.

Mental Health Research Institute, Tomsk

Bokhan N.A.

Nauchno-issledovatel'skiĭ institut psikhicheskogo zdorov'ia Tomskogo nauchnogo tsentra Sibirskogo otdeleniia RAMN

Semke A.V.

Nauchno-issledovatel'skiĭ institut psikhicheskogo zdorov'ia Sibirskogo otdeleniia Rossiĭskoĭ akademii meditsinskikh nauk, Tomsk

Ivanova S.A.

Nauchno-issledovatel'skiĭ institut psikhicheskogo zdorov'ia Sibirskogo otdeleniia Rossiĭskoĭ akademii meditsinskikh nauk, Tomsk

Close metadata

References:

Ayed K. Anti-DNA antibodies: structure and pathogenic role. Archives de l'Institut Pasteur de Tunis. 1999;77(1-4):3-9.
Smeenk R, Brinkman K, Van den Brink H, Termaat R, Berden J, Nossent H, Swaak T. Antibodies to DNA in patients with systemic lupus erythematosus. Their role in the diagnosis, the follow-up and the pathogenesis of the disease. Clinical rheumatology. 1990;9(1):100-110. doi:10.1007/bf02205557.
Ershova N, Garmashova N, Buneva V, Mogel'nitskii A, Doronina O, Doronin B, Konenkova L, Boiko A, Slanova A, Nesterova V, Gusev E, Favorova O, Nevinskii G. Association between DNA antibodies levels in the blood of patients with multiple sclerosis and clinical presentation of the disease. Zhurn. Nevrologii I psikhiatrii im. SS Korsakova. Spetsvyp .«Rasseyannyi skleroz». 2003;(2):25-33.(In Russ)
Krotenko N, Alifirova V, Krotenko N, Ryazantseva A, Boiko A, Ivanova S. Middle mass molecule and antibodies to native and denatured DNA of patients with different types course of multiple sclerosis. Fundamental'nye issledovaniya. 2012;5(2):305-310. (In Russ)
Nasonov, E.L. Clinic and immunopathology of rheumatic diseases. M.: Nauka; 1994. (In Russ)
Nasonova, V.A., Agababova, E. R. Handbook of Rheumatology. M.: Meditsina; 1995. (In Russ)
Carter C. J. Schizophrenia: a pathogenetic autoimmune disease caused by viruses and pathogens and dependent on genes. Journal of pathogens. 2011::1-37. doi:10.4061/2011/128318.
Bergink V, Gibney S, Drexhage H. Autoimmunity, inflammation, and psychosis: a search for peripheral markers. Biological psychiatry. 2014;75(4):324-331. doi:10.1016/j.biopsych.2013.09.037.
Klyushnik T, Brusov O, Burbaeva G, Kolyaskina G. The modern view of the main pathogenetic hypothesis of schizophrenia. Psikhiatriya. 2010;(1):43. (In Russ)
Potvin S, Stip E, Sepehry A, Gendron A, Bah R, Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biological psychiatry. 2008;63(8):801-808. doi:10.1016/j.biopsych.2007.09.024.
Monji A, Kato T, Kanba S. Cytokines and schizophrenia: Microglia hypothesis of schizophrenia. Psychiatry and clinical neurosciences. 2009;63(3):257-265. doi:10.1111/j.1440-1819.2009.01945.x.
Lobacheva O, Naidenova N, Vetlugina T. Cytokines in schizophrenia. Patogenez. 2006;4(1):59-60. (In Russ)
Bhatia M, Dhar N, Agrawal P, Khurana S, Neena B, Malik S. Immunoglobulin profile in schizophrenia. Indian journal of medical sciences. 1992;46(8):239-242.
Villemain F, Magnin M, Feuillet-Fieux M, Zarifian E, Loo H, Bach J. Anti-histone antibodies in schizophrenia and affective disorders. Psychiatry research. 1988;24(1):53-60. doi:10.1016/0165-1781(88)90139-4.
Hinze-Selch D, Becker E, SteinG, Berg P, Mullington J, Holsboer F, Pollmächer T. Effects of clozapine on in vitro immune parameters: a longitudinal study in clozapine-treated schizophrenic patients. Neuropsychopharmacology. 1998;19(2):114-122. doi:10.1016/S0893-133X(98)00006-2.
Semenov S, Chuprikov A, Shapiro F. A atudy of different types of antibodies to DNA in patients with epilepsy and schizophrenia and in normal subjects. Zhurnal nevropatologii i psikhiatrii imeni SS Korsakova (Moscow, Russia: 1952). 1970;71(2):248-253. (In Russ)
Sirota P, Firer M, Schild K, Tanay A, Elizur A, Meytes D, Slor H. Autoantibodies to DNA in multicase families with schizophrenia. Biological psychiatry. 1993;33(6):450-455. doi:10.1016/0006-3223(93)90173-B.
Ismailov T. Study of autoantibodies to DNA in schizophrenia and other neuropsychiatric disorders. Zhurnal nevropatologii I psikhiatrii imeni SS Korsakova (Moscow, Russia: 1952).1971;72(8):1188-1191. (In Rus)
Boiko A.S., Fedorenko O.Yu., Serebrov V.Yu., Semke A.V., Ivanova S.A. Cortisol and antibodies to DNA in schizophrenia patients on the background of antipsychotic therapy. Uspekhi sovremennogo estestvoznaniya. 2013;(9). (In Russ) Available at: http://www.rae.ru/use/?section=content&op=show_article&article_id=10001944. Accessed September 3, 2015.
Deakin J, Lennox B, Zandi M. Antibodies to the N-methyl-D-aspartate receptor and other synaptic proteins in psychosis. Biological psychiatry. 2014;75(4):284-291. doi:10.1016/j.biopsych.2013.07.018.
Pathmanandavel K, Starling J, Merheb V, Ramanathan S, Sinmaz N, Dale R, Brilot F. Antibodies to surface dopamine-2 receptor and N-methyl-d-aspartate receptor in the first episode of acute psychosis in children. Biological psychiatry. 2015;77(6):537-547. doi:10.1016/j.biopsych.2014.07.014.
Steiner J, Schiltz K, Bernstein H, Bogerts B. Antineuronal Antibodies Against Neurotransmitter Receptors and Synaptic Proteins in Schizophrenia: Current Knowledge and Clinical Implications. CNS drugs. 2015;29(3):197-206. doi:10.1007/s40263-015-0233-3.
Schooler N, Kane J. Research diagnoses for tardive dyskinesia. Archives of General Psychiatry. 1982;39(4):486-487. doi:10.1001/archpsyc.1982.04290040080014.
Ivanova, S.A., Fedorenko, O.Yu.,Bokhan, N.A., Lunen, A. Pharmacogenetics of tardive dyskinesia. Tomsk: Izd-vo «Novye pechatnye tekhnologii»; 2015. (In Russ)
Shchigoreva Yu.G, Smirnova L.P., Krotenko N.M., Boiko A.S., Kornetova E.G., Semke A.V. The activity of antioxidant enzymes in red blood cells from peripheral blood in patients with schizophrenia with tardive dyskinesia. Sovremennye problemy nauki i obrazovaniya. 2013;(5):341. (In Russ)
Ivanova S.A., Smirnova L.P., Shchigoreva Yu.G., Boiko A.S., Semke A.V., Uzbekov M.G., Bokhan N.A. Glucose-6-Phosphate Dehydrogenase and Catalase Activities in Erythrocytes of Schizophrenic Patients under Pharmacotherapy with Traditional Antipsychotics. Neurochemical Journal. 2014;8(1):66–70. doi:10.1134/S1819712414010061.
Smirnova L.P. High DNase and proteolytic activity of abzymes from blood of patients with schizophrenia with tardive dyskinesia. Aktual'nye voprosypsi psikhiatrii I narkologii; September 6-7, 2011; Tomsk. (In Russ). Available at: http://www.mental-health.ru/index.php?option=com_content&task=view&id=138&Itemid=49. Accessed September 3, 2015.